¹COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia
²Public Health Service Commissioned Corps, Rockville, Maryland
³Department of Cardiology, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
⁴Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children’s Hospital, Boston, Massachusetts
⁵Division of Pediatric Critical Care Medicine, Department of Pediatrics, New York University Grossman School of Medicine, New York
⁶Division of Pediatric Infectious Diseases, Department of Pediatrics, New York University Grossman School of Medicine, New York
⁷Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora
⁸Division of Critical Care Medicine, Department of Pediatrics, University of Texas Southwestern, Children’s Medical Center Dallas, Dallas
⁹Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children’s Hospital, Columbus, Ohio
¹⁰Department of Anesthesiology and Critical Care Medicine, Division of Pediatric Anesthesiology & Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
¹¹Division of Critical Care, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut
¹²Pediatric Critical Care Division, Maria Fareri Children’s Hospital at Westchester Medical Center and New York Medical College, Valhalla
¹³Department of Pediatrics, Division of Pediatric Critical Care, Bristol-Myers Squibb Children’s Hospital, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey
¹⁴Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham
¹⁵Division of Pediatric Infectious Disease, Department of Pediatrics, Children’s Mercy Kansas City, Kansas City, Missouri
¹⁶Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida
¹⁷Department of Pediatrics, University of North Carolina at Chapel Hill Children’s Hospital
¹⁸Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
¹⁹Division of Infectious Diseases, Department of Pediatrics, Department of Microbiology, University of Mississippi Medical Center, Jackson
²⁰Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
²¹Division of Pediatric Critical Care, Department of Pediatrics, SUNY Downstate Health Sciences University, Brooklyn, New York
²²Division of Pediatric Critical Care, Miller Children’s and Women’s Hospital of Long Beach, Long Beach, California
²³Division of Pediatric Critical Care, University of Minnesota Masonic Children’s Hospital, Minneapolis
²⁴Division of Pediatric Critical Care, Department of Pediatrics, Saint Barnabas Medical Center, Livingston, New Jersey
²⁵Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children’s Hospital, Little Rock
²⁶Division of Hospital Medicine, Department of Pediatrics, Hackensack University Medical Center, Hackensack, New Jersey
²⁷Division of Critical Care Medicine, UCSF Benioff Children’s Hospital Oakland, Oakland, California
²⁸Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center and Children’s Hospital of New Orleans, New Orleans
²⁹Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, Seattle
³⁰Division of Pediatric Critical Care Medicine, Department of Pediatrics, Central Michigan University, Detroit
³¹Pediatric Critical Care Medicine, Department of Pediatrics, Icahn School of Medicine at the Mount Sinai Kravis Children’s Hospital, New York, New York
³²Division of Pediatric Critical Care, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City
³³Division of Critical Care Medicine, Department of Pediatrics, Akron Children’s Hospital, Akron, Ohio
³⁴Department of Pediatrics, Division of Critical Care, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
³⁵Division of Pediatric Critical Care Medicine, MassGeneral Hospital for Children, Harvard Medical School, Boston, Massachusetts
³⁶Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis
³⁷Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children’s Healthcare of Atlanta, Atlanta, Georgia
³⁸Division of Pediatric Critical Care Medicine, Medical University of South Carolina, Charleston
³⁹Division of Critical Care, Department of Anesthesiology and Critical Care, The University of Pennsylvania Perelman School of Medicine, Philadelphia
⁴⁰Division of Critical Care Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
⁴¹Division of Immunology, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
⁴²Departments of Anesthesia and Pediatrics, Harvard Medical School, Boston, Massachusetts

Overcoming COVID-19 Investigatorsfor the

Read article on JAMA Network

Editorial

Comment

Articles

Interviews

Multimedia

Original Investigation

Clinical Characteristics of Children With SARS-CoV-2–Associated Pediatric Inflammatory Multisystem Syndrome

Elizabeth Whittaker, MD; Alasdair Bamford, MD; Julia Kenny, MD; Myrsini Kaforou, PhD; Christine E. Jones, MD; Priyen Shah, MD; Padmanabhan Ramnarayan, MD; Alain Fraisse, MD; Owen Miller, MD; Patrick Davies, MD; Filip Kucera, MD; Joe Brierley, MD; Marilyn McDougall, MD; Michael Carter, MD; Adriana Tremoulet, MD; Chisato Shimizu, MD; Jethro Herberg, MD; Jane C. Burns, MD; Hermione Lyall, MD; Michael Levin, MD; for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia
Research Letter

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Eva W. Cheung, MD; Philip Zachariah, MD, MS; Mark Gorelik, MD; Alexis Boneparth, MD; Steven G. Kernie, MD; Jordan S. Orange, MD, PhD; Joshua D. Milner, MD
Research Letter

Race/Ethnicity Among Children With COVID-19–Associated Multisystem Inflammatory Syndrome

Ellen H. Lee, MD; Kelsey L. Kepler, MPH; Anita Geevarughese, MD, MPH; Rachel Paneth-Pollak, MD, MPH; Marie S. Dorsinville, RN, MPH; Stephanie Ngai, MPH; Kathleen H. Reilly, PhD, MPH
Original Investigation

Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C

Naïm Ouldali, MD, PhD; Julie Toubiana, MD, PhD; Denise Antona, MD; Etienne Javouhey, MD, PhD; Fouad Madhi, MD; Mathie Lorrot, MD, PhD; Pierre-Louis Léger, MD, PhD; Caroline Galeotti, MD, PhD; Caroline Claude, MD; Arnaud Wiedemann, MD, PhD; Noémie Lachaume, MD; Caroline Ovaert, MD, PhD; Morgane Dumortier, MD; Jean-Emmanuel Kahn, MD, PhD; Alexis Mandelcwajg, MD; Lucas Percheron, MD; Blandine Biot, MD; Jeanne Bordet, MD; Marie-Laure Girardin, MD; David Dawei Yang, MD; Marion Grimaud, MD; Mehdi Oualha, MD, PhD; Slimane Allali, MD, PhD; Fanny Bajolle, MD; Constance Beyler, MD; Ulrich Meinzer, MD, PhD; Michael Levy, MD, PhD; Ana-Maria Paulet, MD; Corinne Levy, MD; Robert Cohen, MD; Alexandre Belot, MD, PhD; François Angoulvant, MD, PhD; French Covid-19 Paediatric Inflammation Consortium

Read Article Claim CME

Key Points

Question How do the characteristics and outcomes of children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compare with severe coronavirus disease 2019 (COVID-19)?

Findings In this case series that included 539 patients with MIS-C and 577 patients with severe COVID-19, patients with MIS-C were more likely than those with severe COVID-19 to be 6 to 12 years old, be non-Hispanic Black, and have severe cardiovascular or mucocutaneous involvement and more extreme inflammation.

Meaning The study findings suggest patterns of clinical presentation and organ involvement that distinguish between patients with MIS-C and severe acute COVID-19.

Abstract

Importance Refinement of criteria for multisystem inflammatory syndrome in children (MIS-C) may inform efforts to improve health outcomes.

Objective To compare clinical characteristics and outcomes of children and adolescents with MIS-C vs those with severe coronavirus disease 2019 (COVID-19).

Setting, Design, and Participants Case series of 1116 patients aged younger than 21 years hospitalized between March 15 and October 31, 2020, at 66 US hospitals in 31 states. Final date of follow-up was January 5, 2021. Patients with MIS-C had fever, inflammation, multisystem involvement, and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase–polymerase chain reaction (RT-PCR) or antibody test results or recent exposure with no alternate diagnosis. Patients with COVID-19 had positive RT-PCR test results and severe organ system involvement.

Exposure SARS-CoV-2.

Main Outcomes and Measures Presenting symptoms, organ system complications, laboratory biomarkers, interventions, and clinical outcomes. Multivariable regression was used to compute adjusted risk ratios (aRRs) of factors associated with MIS-C vs COVID-19.

Results Of 1116 patients (median age, 9.7 years; 45% female), 539 (48%) were diagnosed with MIS-C and 577 (52%) with COVID-19. Compared with patients with COVID-19, patients with MIS-C were more likely to be 6 to 12 years old (40.8% vs 19.4%; absolute risk difference [RD], 21.4% [95% CI, 16.1%-26.7%]; aRR, 1.51 [95% CI, 1.33-1.72] vs 0-5 years) and non-Hispanic Black (32.3% vs 21.5%; RD, 10.8% [95% CI, 5.6%-16.0%]; aRR, 1.43 [95% CI, 1.17-1.76] vs White). Compared with patients with COVID-19, patients with MIS-C were more likely to have cardiorespiratory involvement (56.0% vs 8.8%; RD, 47.2% [95% CI, 42.4%-52.0%]; aRR, 2.99 [95% CI, 2.55-3.50] vs respiratory involvement), cardiovascular without respiratory involvement (10.6% vs 2.9%; RD, 7.7% [95% CI, 4.7%-10.6%]; aRR, 2.49 [95% CI, 2.05-3.02] vs respiratory involvement), and mucocutaneous without cardiorespiratory involvement (7.1% vs 2.3%; RD, 4.8% [95% CI, 2.3%-7.3%]; aRR, 2.29 [95% CI, 1.84-2.85] vs respiratory involvement). Patients with MIS-C had higher neutrophil to lymphocyte ratio (median, 6.4 vs 2.7, P < .001), higher C-reactive protein level (median, 152 mg/L vs 33 mg/L; P < .001), and lower platelet count (<150 ×10³ cells/μL [212/523 {41%} vs 84/486 {17%}, P < .001]). A total of 398 patients (73.8%) with MIS-C and 253 (43.8%) with COVID-19 were admitted to the intensive care unit, and 10 (1.9%) with MIS-C and 8 (1.4%) with COVID-19 died during hospitalization. Among patients with MIS-C with reduced left ventricular systolic function (172/503, 34.2%) and coronary artery aneurysm (57/424, 13.4%), an estimated 91.0% (95% CI, 86.0%-94.7%) and 79.1% (95% CI, 67.1%-89.1%), respectively, normalized within 30 days.

Conclusions and Relevance This case series of patients with MIS-C and with COVID-19 identified patterns of clinical presentation and organ system involvement. These patterns may help differentiate between MIS-C and COVID-19.

Claim CME

Buy This Activity

Article Information

Corresponding Author: Adrienne G. Randolph, MD, Boston Children’s Hospital, 300 Longwood Ave, Bader 634, Boston, MA 02115 (adrienne.randolph@childrens.harvard.edu).

Accepted for Publication: February 8, 2021.

Published Online: February 24, 2021. doi:10.1001/jama.2021.2091

Author Contributions: Dr Patel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Feldstein, Tenforde, and Friedman contributed equally, as did Drs Patel, Newburger, and Randolph.

Concept and design: Feldstein, Li, Walker, Hobbs, Halasa, Doymaz, Horwitz, Patel, Randolph.

Acquisition, analysis, or interpretation of data: Feldstein, Tenforde, Friedman, Newhams, Rose, Dapul, Soma, Maddux, Mourani, Bowens, Maamari, Hall, Riggs, Giuliano, Singh, Li, Kong, Schuster, McLaughlin, Schwartz, Loftis, Hobbs, Halasa, Babbitt, Hume, Gertz, Irby, Clouser, Cvijanovich, Bradford, Smith, Heidemann, Zackai, Wellnitz, Nofziger, Horwitz, Carroll, Rowan, Tarquinio, Mack, Fitzgerald, Coates, Jackson, Young, Son, Patel, Newburger, Randolph.

Drafting of the manuscript: Feldstein, Tenforde, Friedman, Rose, Doymaz, Jackson, Young, Patel, Newburger, Randolph.

Critical revision of the manuscript for important intellectual content: Feldstein, Tenforde, Friedman, Newhams, Dapul, Soma, Maddux, Mourani, Bowens, Maamari, Hall, Riggs, Giuliano, Singh, Li, Kong, Schuster, McLaughlin, Schwartz, Walker, Loftis, Hobbs, Halasa, Doymaz, Babbitt, Hume, Gertz, Irby, Clouser, Cvijanovich, Bradford, Smith, Heidemann, Zackai, Wellnitz, Nofziger, Horwitz, Carroll, Rowan, Tarquinio, Mack, Fitzgerald, Coates, Son, Patel, Newburger, Randolph.

Statistical analysis: Feldstein, Tenforde, Rose, Giuliano, Zackai, Jackson, Young, Randolph.

Obtained funding: Patel, Randolph.

Administrative, technical, or material support: Feldstein, Tenforde, Newhams, Rose, Dapul, Maamari, Hall, Riggs, Kong, McLaughlin, Schwartz, Loftis, Hobbs, Doymaz, Babbitt, Hume, Gertz, Irby, Bradford, Zackai, Wellnitz, Carroll, Fitzgerald, Coates, Son, Randolph.

Supervision: Feldstein, Friedman, Newhams, Singh, Hobbs, Cvijanovich, Horwitz, Carroll, Coates, Patel, Randolph.

Conflict of Interest Disclosures: Dr Maddux reported receiving grants from National Institutes of Health (NIH) (K23HD096018) and Francis Family Foundation (Parker B. Francis Fellowship) during the conduct of the study. Dr Mourani reported receiving grants from the NIH. Dr Hall reported receiving personal fees from LaJolla Pharmaceuticals for service on a data safety and monitoring board outside the submitted work. Dr Schuster reported receiving grants from Merck outside the submitted work. Dr Halasa reported receiving grants from Sanofi, Quindell, and Quidel; personal fees from Genentech (educational grant); and hemagglutination inhibition and microneutralization testing and vaccine donation from Sanofi outside the submitted work. Dr Cvijanovich reported receiving grants from Cincinnati Children’s Hospital Medical Center outside the submitted work. Dr Rowan reported receiving grants from the National Heart, Lung, and Blood Institute (K23HL150244-01A1) outside the submitted work. Dr Fitzgerald reported receiving grants from an NIH career development award outside the submitted work. Dr Newburger reported serving as chair of events adjudication committee for a trial on apixaban in children for Pfizer and Bristol-Myers Squibb, as chair of events adjudication committee for a trial of Entresto in children for Novartis, and as a steering committee member for a trial of endoxaban for Daiichi-Sankyo outside the submitted work. Dr Randolph reported receiving royalties from UpToDate and personal fees from LaJolla Pharma Inc outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by the Centers for Disease Control and Prevention (CDC) under a contract to Boston Children’s Hospital.

Role of the Funder/Sponsor: The CDC designed and conducted the study; collected, managed, analyzed, and interpreted the data; prepared, reviewed, and approved the manuscript; and had a role in the decision to submit the manuscript for publication and journal choice, and had the right to veto publication.

Group Information: The Overcoming COVID-19 Investigators are listed in the eAppendix in the Supplement.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

Additional Contributions: We appreciate and thank the many research coordinators at the Overcoming COVID-19 hospitals who assisted in data collection for this study. We thank the leadership of the Pediatric Acute Lung Injury and Sepsis Investigator’s (PALISI) Network for their ongoing support.

References

NYC Health. 2020 Health alert 13: pediatric multi-system inflammatory syndrome potentially associated with COVID-19. Published May 4, 2020. Accessed December 3, 2020. https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-system-inflammatory-syndrome.pdf

Riphagen S , Gomez X , Gonzalez-Martinez C , Wilkinson N , Theocharis P . Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-1608. doi:10.1016/S0140-6736(20)31094-1 PubMed Google Scholar Crossref

Verdoni L , Mazza A , Gervasoni A , et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-X PubMed Google Scholar Crossref

Centers for Disease Control and Prevention. Emergency preparedness and response: HAN00432. Published May 14, 2020. Accessed December 3, 2020. https://emergency.cdc.gov/han/2020/han00432.asp

Feldstein LR , Rose EB , Horwitz SM , et al; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680 PubMed Google Scholar Crossref

Dufort EM , Koumans EH , Chow EJ , et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756 PubMed Google Scholar Crossref

Sperotto F , Friedman KG , Son MBF , VanderPluym CJ , Newburger JW , Dionne A . Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021;180(2):307-322. doi:10.1007/s00431-020-03766-6 PubMed Google Scholar Crossref

Swann OV , Holden KA , Turtle L , et al; ISARIC4C Investigators. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020;370:m3249. doi:10.1136/bmj.m3249 PubMed Google Scholar Crossref

Henderson LA , Canna SW , Friedman KG , et al. American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19: version 2. Arthritis Rheumatol. Published online December 5, 2020. PubMed Google Scholar

10.

Valverde I , Singh Y , Sanchez-de-Toledo J , et al; AEPC COVID-19 Rapid Response Team. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021;143(1):21-32. doi:10.1161/CIRCULATIONAHA.120.050065 PubMed Google Scholar Crossref

11.

Fernandes DM , Oliveira CR , Guerguis S , et al; Tri-State Pediatric COVID-19 Research Consortium. SARS-CoV-2 clinical syndromes and predictors of disease severity in hospitalized children and youth. J Pediatr. Published online November 14, 2020. doi:10.1016/j.jpeds.2020.11.016 PubMed Google Scholar

12.

Lu X , Zhang L , Du H , et al; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-1665. doi:10.1056/NEJMc2005073 PubMed Google Scholar Crossref

13.

Götzinger F , Santiago-García B , Noguera-Julián A , et al; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-661. doi:10.1016/S2352-4642(20)30177-2 PubMed Google Scholar Crossref

14.

Godfred-Cato S , Bryant B , Leung J , et al; California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children: United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074-1080. doi:10.15585/mmwr.mm6932e2 PubMed Google Scholar Crossref

15.

Castagnoli R , Votto M , Licari A , et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020;174(9):882-889. doi:10.1001/jamapediatrics.2020.1467 PubMed Google Scholar Crossref

16.

Office of the Federal Register; Government Publishing Office. Electronic code of federal regulations. Accessed February 21, 2021. https://www.ecfr.gov/cgi-bin/text-idx?SID=fc043bd2812f0775fa80066558a6bbcf&mc=true&node=pt45.1.46&rgn=div5#se45.1.46_1102

17.

Centers for Disease Control and Prevention. Partner updates: case definition for MISC-C. Accessed December 4, 2020. https://www.cdc.gov/mis-c/hcp/

18.

Leteurtre S , Duhamel A , Grandbastien B , et al. Daily estimation of the severity of multiple organ dysfunction syndrome in critically ill children. CMAJ. 2010;182(11):1181-1187. doi:10.1503/cmaj.081715 PubMed Google Scholar Crossref

19.

World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Accessed February 4, 2021. https://www.who.int/vmnis/indicators/haemoglobin.pdf

20.

Centers for Disease Control and Prevention. Defining childhood obesity: BMI for children and teens. Accessed September 21, 2020. https://www.cdc.gov/obesity/childhood/defining.html

21.

Lopez L , Colan SD , Frommelt PC , et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23(5):465-495. doi:10.1016/j.echo.2010.03.019 PubMed Google Scholar Crossref

22.

McCrindle BW , Rowley AH , Newburger JW , et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484 PubMed Google Scholar Crossref

23.

Matics TJ , Sanchez-Pinto LN . Adaptation and validation of a pediatric Sequential Organ Failure Assessment Score and evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr. 2017;171(10):e172352. doi:10.1001/jamapediatrics.2017.2352 PubMed Google Scholar

24.

Linkins LA , Dans AL , Moores LK , et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e495S-e530S. doi:10.1378/chest.11-2303 PubMed Google Scholar Crossref

25.

Spiegelman D , Hertzmark E . Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200. doi:10.1093/aje/kwi188 PubMed Google Scholar Crossref

26.

Norton EC , Miller MM , Kleinman LC . Computing adjusted risk ratios and risk differences in Stata. The Stata Journal. 2013;13(3):492-509.Google Scholar Crossref

27.

Lee EH , Kepler KL , Geevarughese A , et al. Race/ethnicity among children with COVID-19-associated multisystem inflammatory syndrome. JAMA Netw Open. 2020;3(11):e2030280. doi:10.1001/jamanetworkopen.2020.30280 PubMed Google Scholar

28.

Portman MA , Dahdah NS , Slee A , et al; EATAK Investigators. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics. 2019;143(6):e20183675. doi:10.1542/peds.2018-3675 PubMed Google Scholar

29.

Clark DE , Denby KJ , Kaufman LM , et al. Predictors of intravenous immunoglobulin nonresponse and racial disparities in Kawasaki disease. Pediatr Infect Dis J. 2018;37(12):1227-1234. doi:10.1097/INF.0000000000002019 PubMed Google Scholar Crossref

30.

Matsubara D , Kauffman HL , Wang Y , et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol. 2020;76(17):1947-1961. doi:10.1016/j.jacc.2020.08.056 PubMed Google Scholar Crossref

31.

Belhadjer Z , Méot M , Bajolle F , et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142(5):429-436. doi:10.1161/CIRCULATIONAHA.120.048360 PubMed Google Scholar Crossref

32.

Theocharis P , Wong J , Pushparajah K , et al. Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19. Eur Heart J Cardiovasc Imaging. 2020;jeaa212. doi:10.1093/ehjci/jeaa212 PubMed Google Scholar

33.

Freaney PM , Shah SJ , Khan SS . COVID-19 and heart failure with preserved ejection fraction. JAMA. 2020. doi:10.1001/jama.2020.17445 PubMed Google Scholar

34.

Muniz JC , Dummer K , Gauvreau K , Colan SD , Fulton DR , Newburger JW . Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013;6(2):239-244. doi:10.1161/CIRCIMAGING.112.000159 PubMed Google Scholar Crossref

35.

Shulman ST , Rowley AH . Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11(8):475-482. doi:10.1038/nrrheum.2015.54 PubMed Google Scholar Crossref

36.

Alsaied T , Tremoulet AH , Burns JC , et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation. 2021;143(1):78-88. doi:10.1161/CIRCULATIONAHA.120.049836 PubMed Google Scholar Crossref

37.

Guo T , Fan Y , Chen M , et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017 PubMed Google Scholar Crossref

38.

Rowley AH . Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453-454. doi:10.1038/s41577-020-0367-5 PubMed Google Scholar Crossref

39.

Lee PY , Day-Lewis M , Henderson LA , et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130(11):5942-5950. doi:10.1172/JCI141113 PubMed Google Scholar Crossref

40.

Belhadjer Z , Auriau J , Méot M , et al. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142(23):2282-2284. doi:10.1161/CIRCULATIONAHA.120.050147 PubMed Google Scholar Crossref

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

Kawasaki Disease and SARS-CoV-2–Related Inflammatory Multisystem Syndrome in Children

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Clinical Characteristics of Children With SARS-CoV-2–Associated Pediatric Inflammatory Multisystem Syndrome

Race/Ethnicity Among Children With COVID-19–Associated Multisystem Inflammatory Syndrome

Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C

See More

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

Kawasaki Disease and SARS-CoV-2–Related Inflammatory Multisystem Syndrome in Children

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Clinical Characteristics of Children With SARS-CoV-2–Associated Pediatric Inflammatory Multisystem Syndrome

Race/Ethnicity Among Children With COVID-19–Associated Multisystem Inflammatory Syndrome

Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C

See More

See More About

If you are not a JN Learning subscriber, you can either:

A subscription to JN Learning (CME from JAMA Network) provides:

Sign in to access

If you are not a JN Learning subscriber, you can either:

Sign in to customize your interests

With a personal account, you can:

Name Your Search

Sign in to save your search

With a personal account, you can:

Lookup An Activity

My Saved Searches

Sign in to customize your interests

With a personal account, you can:

Purchase access